Corteva vs Bayer AG NA: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Corteva Inc (CTVA)

Q3 202610 Jul – 1 Oct 2026

▲3▼1

Corteva raised guidance and split off seeds, but PFAS lawsuits clouded the quarter

Raised 2026 guidance on strong first-half results Corteva lifted its 2026 outlook after first-half sales rose 4%, EBITDA 10% and EPS 14%, with cost cuts adding over $160 million to EBITDA. The company also said new crop protection products are nearing $2 billion in 2026 revenue.
This is the core positive business update that drove the quarter.
Seed and crop protection split completed October 1 Corteva separated its seed and crop protection businesses on October 1, creating a new company called Vylor. Management says the split should unlock value by letting each business focus on its own strategy and growth.
This is a major structural event that could change how investors value the company.
Pipeline strengthened by Globachem JV and Inari settlement A new joint venture with Globachem adds promising crop protection products to the pipeline. Separately, a lawsuit settlement with Inari protected Corteva's seed intellectual property, removing a legal threat to its seed business.
These moves support future growth and reduce legal risk for the core business.
PFAS litigation and spin-off challenge create uncertainty PFAS lawsuits remain a major overhang, including a $2.5 billion New Jersey settlement, a New York suit, and a $455 million North Carolina settlement. State attorneys general are challenging the Vylor spin-off, saying it dodges PFAS liabilities, so the separation may not proceed as planned.
This is the biggest risk that could hurt the stock and derail the spin-off.

September 202610 Sep – 1 Oct 2026

▲3

Corteva completes Vylor spin-off, settles PFAS and seed lawsuits

PFAS settlement removes overhang Corteva and partners settled North Carolina PFAS claims for $455 million, with Corteva's share covered by existing reserves and future escrow obligations satisfied. This removes a major legal uncertainty that had weighed on the stock, making the company's liabilities clearer and reducing risk for investors.
Resolving a major legal overhang directly reduces uncertainty and supports the stock price.
Vylor spin-off approved but challenged by state AGs Corteva's board approved spinning off its seed unit as Vylor, but state attorneys general sued, claiming the move dodges PFAS liabilities. The spin-off could unlock value by focusing Corteva on crop protection, but the legal challenge creates uncertainty about whether it can proceed as planned.
The spin-off is a major strategic event with both potential upside and legal risk.
Crop protection joint venture with Globachem Corteva formed a 50/50 joint venture with Globachem to develop and sell new crop protection products in Europe and the Americas. Corteva contributes late-stage technology, which could strengthen its product pipeline and future revenue, though new products won't launch until the early 2030s.
This partnership expands Corteva's crop protection business and pipeline, a positive long-term driver.
Inari seed lawsuit settled in Corteva's favor Corteva settled its lawsuit against Inari, requiring Inari to destroy Corteva seed material and assign related intellectual property to Corteva. This reinforces Corteva's patent and contract rights over its seed technology, protecting its competitive advantage and reducing legal risk.
The settlement strengthens Corteva's intellectual property position and removes a legal dispute.

Latest10 Sep – 1 Oct 2026

▲3

Corteva completes Vylor spin-off, settles PFAS and seed lawsuits

PFAS settlement removes overhang Corteva and partners settled North Carolina PFAS claims for $455 million, with Corteva's share covered by existing reserves and future escrow obligations satisfied. This removes a major legal uncertainty that had weighed on the stock, making the company's liabilities clearer and reducing risk for investors.
Resolving a major legal overhang directly reduces uncertainty and supports the stock price.
Vylor spin-off approved but challenged by state AGs Corteva's board approved spinning off its seed unit as Vylor, but state attorneys general sued, claiming the move dodges PFAS liabilities. The spin-off could unlock value by focusing Corteva on crop protection, but the legal challenge creates uncertainty about whether it can proceed as planned.
The spin-off is a major strategic event with both potential upside and legal risk.
Crop protection joint venture with Globachem Corteva formed a 50/50 joint venture with Globachem to develop and sell new crop protection products in Europe and the Americas. Corteva contributes late-stage technology, which could strengthen its product pipeline and future revenue, though new products won't launch until the early 2030s.
This partnership expands Corteva's crop protection business and pipeline, a positive long-term driver.
Inari seed lawsuit settled in Corteva's favor Corteva settled its lawsuit against Inari, requiring Inari to destroy Corteva seed material and assign related intellectual property to Corteva. This reinforces Corteva's patent and contract rights over its seed technology, protecting its competitive advantage and reducing legal risk.
The settlement strengthens Corteva's intellectual property position and removes a legal dispute.

July 202610 Jul – 7 Aug 2026

▲3▼1

Corteva Raises Guidance, Splits in October, Faces PFAS Costs

Full-year 2026 guidance raised on strong first half Corteva lifted its 2026 outlook after first-half sales rose 4%, EBITDA grew 10%, and EPS climbed 14%. Cost cuts added over $160 million to EBITDA. Higher profit expectations make the stock more attractive, pushing CTVA up.
This is the core new positive event that directly lifts earnings expectations and the stock.
New crop protection products near $2 billion in 2026 revenue Corteva expects new crop protection products to bring in almost $2 billion in 2026, with seven new active ingredients planned and hybrid wheat launching in 2027. This shows strong demand for its products, supporting higher future sales and the stock price.
It shows a concrete new growth driver that supports the bull case for CTVA.
Seed and Crop Protection separation on track for October 1 Corteva confirmed its split into two companies—Vylor (seeds) and Corteva (crop protection)—remains on schedule for October 1, with separation costs largely offset by synergies. A cleaner structure can unlock value, helping the stock.
The separation is a major strategic catalyst that investors are watching closely.
PFAS lawsuits and $2.5 billion settlement create regulatory overhang New York sued Corteva and other chemical makers over PFAS contamination, seeking cleanup costs. A court also approved a $2.5 billion New Jersey PFAS settlement involving Corteva as a DuPont spinoff. These legal liabilities weigh on the stock by adding uncertainty and potential costs.
It is the main negative force this period, balancing the positive earnings and growth news.

10 Jul – 7 Aug 2026

▲3▼1

Corteva Raises Guidance, Splits in October, Faces PFAS Costs

Full-year 2026 guidance raised on strong first half Corteva lifted its 2026 outlook after first-half sales rose 4%, EBITDA grew 10%, and EPS climbed 14%. Cost cuts added over $160 million to EBITDA. Higher profit expectations make the stock more attractive, pushing CTVA up.
This is the core new positive event that directly lifts earnings expectations and the stock.
New crop protection products near $2 billion in 2026 revenue Corteva expects new crop protection products to bring in almost $2 billion in 2026, with seven new active ingredients planned and hybrid wheat launching in 2027. This shows strong demand for its products, supporting higher future sales and the stock price.
It shows a concrete new growth driver that supports the bull case for CTVA.
Seed and Crop Protection separation on track for October 1 Corteva confirmed its split into two companies—Vylor (seeds) and Corteva (crop protection)—remains on schedule for October 1, with separation costs largely offset by synergies. A cleaner structure can unlock value, helping the stock.
The separation is a major strategic catalyst that investors are watching closely.
PFAS lawsuits and $2.5 billion settlement create regulatory overhang New York sued Corteva and other chemical makers over PFAS contamination, seeking cleanup costs. A court also approved a $2.5 billion New Jersey PFAS settlement involving Corteva as a DuPont spinoff. These legal liabilities weigh on the stock by adding uncertainty and potential costs.
It is the main negative force this period, balancing the positive earnings and growth news.

Bayer AG NA (BAYN.XETRA)

Q3 202628 Jun – 2 Oct 2026

▲2

Bayer cuts legal risk, advances pipeline, but valuation debate rages

Legal risk reduction Bayer sold a €3bn stake in its contraceptives business to Apollo and won court approval for its $7.25bn Roundup settlement, reducing legal uncertainty. It also revived mRNA patent lawsuits against Pfizer, BioNTech, and Moderna.
These actions directly lower Bayer's legal overhang, a key factor for investors.
Pipeline and product progress The FDA approved sevabertinib for first-line lung cancer and expanded Kerendia to type 1 diabetes kidney disease. Lynkuet received Priority Review, and Bayer advanced cardiac imaging, atrial fibrillation, and a Canadian approval.
New approvals and pipeline advances support future revenue growth.
Strategic investments and trade actions Bayer sought US duties on Chinese glyphosate imports and announced a $2.2bn Ohio plant. While these moves aim to protect its market, farm groups oppose the duties, creating uncertainty.
These initiatives have potential benefits but also face opposition, leading to mixed impact.
Valuation dispute Analysts remain divided: bulls see 21% upside, bears see 45% downside, amid pending Roundup settlement approval and litigation provisions. This reflects ongoing uncertainty despite positive developments.
The wide valuation gap highlights conflicting views on Bayer's risk profile.

September 202616 Sep – 2 Oct 2026

▲4

Bayer advances pipeline, legal wins, and US investment

FDA expands Kerendia to type 1 diabetes kidney disease The FDA approved Kerendia for chronic kidney disease in type 1 diabetes, its third US approval. This opens a new patient group for a drug already growing fast, supporting future sales and profit, which helps lift the shares.
New regulatory approval expands a key drug's market, directly supporting Bayer's growth outlook.
Monsanto mRNA patent lawsuits against Pfizer, BioNTech, Moderna proceed A judge rejected bids to dismiss Monsanto's patent suits over mRNA technology used in COVID-19 vaccines. This keeps alive a potential new revenue stream from licensing or damages, reducing legal uncertainty and supporting the stock.
New legal development that could bring in money and shows Bayer's patents have value.
FDA grants Priority Review to Lynkuet for breast cancer hot flashes The FDA accepted Bayer's application and granted Priority Review for Lynkuet to treat hot flashes in breast cancer patients on endocrine therapy. If approved, it would be the first such treatment, opening a new market and boosting growth prospects.
New regulatory milestone for a potential first-in-class treatment, adding to Bayer's pipeline value.
Bayer to invest $2.2 billion in new Ohio manufacturing site Bayer plans a $2.2 billion pharmaceutical plant in Ohio, creating 600 jobs and supporting its oncology, heart, and kidney drug portfolio. This shows commitment to its largest market and long-term growth, which investors view favorably.
New major capital investment signals confidence in future growth and US expansion.

Latest16 Sep – 2 Oct 2026

▲4

Bayer advances pipeline, legal wins, and US investment

FDA expands Kerendia to type 1 diabetes kidney disease The FDA approved Kerendia for chronic kidney disease in type 1 diabetes, its third US approval. This opens a new patient group for a drug already growing fast, supporting future sales and profit, which helps lift the shares.
New regulatory approval expands a key drug's market, directly supporting Bayer's growth outlook.
Monsanto mRNA patent lawsuits against Pfizer, BioNTech, Moderna proceed A judge rejected bids to dismiss Monsanto's patent suits over mRNA technology used in COVID-19 vaccines. This keeps alive a potential new revenue stream from licensing or damages, reducing legal uncertainty and supporting the stock.
New legal development that could bring in money and shows Bayer's patents have value.
FDA grants Priority Review to Lynkuet for breast cancer hot flashes The FDA accepted Bayer's application and granted Priority Review for Lynkuet to treat hot flashes in breast cancer patients on endocrine therapy. If approved, it would be the first such treatment, opening a new market and boosting growth prospects.
New regulatory milestone for a potential first-in-class treatment, adding to Bayer's pipeline value.
Bayer to invest $2.2 billion in new Ohio manufacturing site Bayer plans a $2.2 billion pharmaceutical plant in Ohio, creating 600 jobs and supporting its oncology, heart, and kidney drug portfolio. This shows commitment to its largest market and long-term growth, which investors view favorably.
New major capital investment signals confidence in future growth and US expansion.

August 202617 Aug – 10 Sep 2026

▲4

Bayer advances drug pipeline and Roundup settlement, lifting sentiment

Roundup settlement clears court hurdle A US appeals court rejected a challenge to Bayer's $7.25 billion Roundup settlement, keeping the case on track for a September 14 review. This reduces the legal cloud that has weighed on the shares for years, though final approval is still pending.
It is the biggest single overhang on Bayer's stock and the news directly reduces that uncertainty.
FDA approves sevabertinib for first-line lung cancer Bayer won FDA accelerated approval for sevabertinib in first-line HER2-mutant NSCLC, based on a 75% response rate. This expands the drug's use to newly diagnosed patients, opening a larger market and supporting future sales growth.
A new approval for a key cancer drug directly adds a new revenue opportunity and validates Bayer's pipeline.
Pipeline progress in cardiac imaging and atrial fibrillation Bayer's Phase III REVEAL study for a cardiac amyloidosis imaging agent met its goals, and a Phase II trial began for a new atrial fibrillation drug. Both are early but show Bayer's research engine is producing candidates beyond its current products.
These are new clinical milestones that strengthen the long-term pipeline story investors are watching.
Expanded Canadian approval and biofuel partnership Canada broadened approval of LYNKUET for breast-cancer-related hot flashes, adding a new patient group. Separately, Bayer partnered with Neste to scale winter canola for biofuels, creating a new market for its seeds and crop technology.
Both are fresh commercial expansions that add incremental revenue streams in health and agriculture.

17 Aug – 10 Sep 2026

▲4

Bayer advances drug pipeline and Roundup settlement, lifting sentiment

Roundup settlement clears court hurdle A US appeals court rejected a challenge to Bayer's $7.25 billion Roundup settlement, keeping the case on track for a September 14 review. This reduces the legal cloud that has weighed on the shares for years, though final approval is still pending.
It is the biggest single overhang on Bayer's stock and the news directly reduces that uncertainty.
FDA approves sevabertinib for first-line lung cancer Bayer won FDA accelerated approval for sevabertinib in first-line HER2-mutant NSCLC, based on a 75% response rate. This expands the drug's use to newly diagnosed patients, opening a larger market and supporting future sales growth.
A new approval for a key cancer drug directly adds a new revenue opportunity and validates Bayer's pipeline.
Pipeline progress in cardiac imaging and atrial fibrillation Bayer's Phase III REVEAL study for a cardiac amyloidosis imaging agent met its goals, and a Phase II trial began for a new atrial fibrillation drug. Both are early but show Bayer's research engine is producing candidates beyond its current products.
These are new clinical milestones that strengthen the long-term pipeline story investors are watching.
Expanded Canadian approval and biofuel partnership Canada broadened approval of LYNKUET for breast-cancer-related hot flashes, adding a new patient group. Separately, Bayer partnered with Neste to scale winter canola for biofuels, creating a new market for its seeds and crop technology.
Both are fresh commercial expansions that add incremental revenue streams in health and agriculture.

July 202628 Jun – 22 Jul 2026

▲3

Bayer cuts legal risk, raises cash, and expands pipeline

Bayer seeks US duties on Chinese glyphosate Bayer asked Washington to impose duties on Chinese-made glyphosate, saying it is sold at artificially low prices. If successful, this would reduce competition and protect Bayer's US glyphosate business, supporting future earnings. However, US farm groups oppose the move, warning of higher costs for farmers.
This is a new regulatory push that could directly benefit Bayer's crop science earnings by limiting cheap imports.
Bayer sells €3bn minority stake in contraceptives unit to Apollo Bayer sold a non-controlling stake in its long-acting reversible contraceptives business to Apollo for €3 billion. This strengthens Bayer's capital structure and financial flexibility, helping it manage bond maturities and litigation costs. Bayer keeps full operational control of the unit.
This new deal brings in significant cash, reducing balance sheet pressure and supporting the stock.
Bayer partners with Kairos Pharma on prostate cancer combination Bayer will evaluate its radiopharmaceutical XOFIGO with Kairos Pharma's ENV-105 in metastatic prostate cancer. The combination aims to overcome drug resistance and could expand XOFIGO's use in a market worth up to $1.3 billion. This supports Bayer's oncology pipeline.
This new collaboration could boost Bayer's pharmaceutical growth prospects, a positive for long-term revenue.
Bayer stock rallies 83% but valuation debate continues Bayer shares have surged 83% over the past year, yet valuation screens still show a discount. Bulls see the stock as 21% undervalued, while bears argue it is 45% overvalued due to ongoing litigation risks and provisions. The debate centers on whether the market is correctly pricing these risks.
This highlights the tug-of-war between Bayer's strong rally and lingering legal concerns, giving a balanced view of what drives the stock.

28 Jun – 22 Jul 2026

▲3

Bayer cuts legal risk, raises cash, and expands pipeline

Bayer seeks US duties on Chinese glyphosate Bayer asked Washington to impose duties on Chinese-made glyphosate, saying it is sold at artificially low prices. If successful, this would reduce competition and protect Bayer's US glyphosate business, supporting future earnings. However, US farm groups oppose the move, warning of higher costs for farmers.
This is a new regulatory push that could directly benefit Bayer's crop science earnings by limiting cheap imports.
Bayer sells €3bn minority stake in contraceptives unit to Apollo Bayer sold a non-controlling stake in its long-acting reversible contraceptives business to Apollo for €3 billion. This strengthens Bayer's capital structure and financial flexibility, helping it manage bond maturities and litigation costs. Bayer keeps full operational control of the unit.
This new deal brings in significant cash, reducing balance sheet pressure and supporting the stock.
Bayer partners with Kairos Pharma on prostate cancer combination Bayer will evaluate its radiopharmaceutical XOFIGO with Kairos Pharma's ENV-105 in metastatic prostate cancer. The combination aims to overcome drug resistance and could expand XOFIGO's use in a market worth up to $1.3 billion. This supports Bayer's oncology pipeline.
This new collaboration could boost Bayer's pharmaceutical growth prospects, a positive for long-term revenue.
Bayer stock rallies 83% but valuation debate continues Bayer shares have surged 83% over the past year, yet valuation screens still show a discount. Bulls see the stock as 21% undervalued, while bears argue it is 45% overvalued due to ongoing litigation risks and provisions. The debate centers on whether the market is correctly pricing these risks.
This highlights the tug-of-war between Bayer's strong rally and lingering legal concerns, giving a balanced view of what drives the stock.

Q2 202617 Jun – 26 Jun 2026

▲4

Supreme Court Roundup win reshapes Bayer's legal risk

Supreme Court ends failure-to-warn Roundup claims The US Supreme Court ruled 7-2 that federal pesticide law blocks state failure-to-warn claims, throwing out a $1.25 million verdict and barring similar future suits. This removes the biggest legal cloud over Bayer, cutting years of litigation costs and uncertainty, and sent the stock up about 17-20%.
This is the single biggest new event and the main reason the stock moved sharply.
Roundup settlement still needs final court approval A legal challenge to Bayer's proposed $7.25 billion Roundup settlement stays in Missouri state court, with a final approval hearing on July 9. The Supreme Court win covers most claims, but this settlement is still a step Bayer must clear, so some legal uncertainty remains.
It is the main counterweight to the Supreme Court win and tells readers the legal story is not fully closed.
Bayer buys Perfuse eye-disease drug Bayer completed its acquisition of Perfuse Therapeutics for $300 million upfront, up to $2.45 billion with milestones, gaining a Phase II eye implant for glaucoma and diabetic retinopathy. This adds a new late-stage asset to Bayer's pharmaceutical pipeline, supporting longer-term growth.
It is a new pipeline-strengthening deal that affects Bayer's future earnings potential.
Bayer partners with Iambic on AI drug discovery Bayer will use Iambic Therapeutics' AI platform to find new small-molecule drugs for hard-to-treat targets, aiming to speed up early research. This could make Bayer's drug pipeline more productive over time, a positive for future revenue, though financial terms were not disclosed.
It is a new technology collaboration that could improve Bayer's long-term drug discovery output.

June 202617 Jun – 26 Jun 2026

▲4

Supreme Court Roundup win reshapes Bayer's legal risk

Supreme Court ends failure-to-warn Roundup claims The US Supreme Court ruled 7-2 that federal pesticide law blocks state failure-to-warn claims, throwing out a $1.25 million verdict and barring similar future suits. This removes the biggest legal cloud over Bayer, cutting years of litigation costs and uncertainty, and sent the stock up about 17-20%.
This is the single biggest new event and the main reason the stock moved sharply.
Roundup settlement still needs final court approval A legal challenge to Bayer's proposed $7.25 billion Roundup settlement stays in Missouri state court, with a final approval hearing on July 9. The Supreme Court win covers most claims, but this settlement is still a step Bayer must clear, so some legal uncertainty remains.
It is the main counterweight to the Supreme Court win and tells readers the legal story is not fully closed.
Bayer buys Perfuse eye-disease drug Bayer completed its acquisition of Perfuse Therapeutics for $300 million upfront, up to $2.45 billion with milestones, gaining a Phase II eye implant for glaucoma and diabetic retinopathy. This adds a new late-stage asset to Bayer's pharmaceutical pipeline, supporting longer-term growth.
It is a new pipeline-strengthening deal that affects Bayer's future earnings potential.
Bayer partners with Iambic on AI drug discovery Bayer will use Iambic Therapeutics' AI platform to find new small-molecule drugs for hard-to-treat targets, aiming to speed up early research. This could make Bayer's drug pipeline more productive over time, a positive for future revenue, though financial terms were not disclosed.
It is a new technology collaboration that could improve Bayer's long-term drug discovery output.

17 Jun – 26 Jun 2026

▲4

Supreme Court Roundup win reshapes Bayer's legal risk

Supreme Court ends failure-to-warn Roundup claims The US Supreme Court ruled 7-2 that federal pesticide law blocks state failure-to-warn claims, throwing out a $1.25 million verdict and barring similar future suits. This removes the biggest legal cloud over Bayer, cutting years of litigation costs and uncertainty, and sent the stock up about 17-20%.
This is the single biggest new event and the main reason the stock moved sharply.
Roundup settlement still needs final court approval A legal challenge to Bayer's proposed $7.25 billion Roundup settlement stays in Missouri state court, with a final approval hearing on July 9. The Supreme Court win covers most claims, but this settlement is still a step Bayer must clear, so some legal uncertainty remains.
It is the main counterweight to the Supreme Court win and tells readers the legal story is not fully closed.
Bayer buys Perfuse eye-disease drug Bayer completed its acquisition of Perfuse Therapeutics for $300 million upfront, up to $2.45 billion with milestones, gaining a Phase II eye implant for glaucoma and diabetic retinopathy. This adds a new late-stage asset to Bayer's pharmaceutical pipeline, supporting longer-term growth.
It is a new pipeline-strengthening deal that affects Bayer's future earnings potential.
Bayer partners with Iambic on AI drug discovery Bayer will use Iambic Therapeutics' AI platform to find new small-molecule drugs for hard-to-treat targets, aiming to speed up early research. This could make Bayer's drug pipeline more productive over time, a positive for future revenue, though financial terms were not disclosed.
It is a new technology collaboration that could improve Bayer's long-term drug discovery output.